XFRA NEW INSTRUMENTS AVAILABLE ON XETRA

XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 03.09.2024

The following instruments on XETRA do have their first trading 03.09.2024
Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.09.2024

Aktien

1 AU000000ICI5 iCandy Interactive Ltd.

2 CA75941A1012 Rektron Group Inc.
3 US5768103039 Matinas BioPharma Holdings Inc.
4 US6876041087 Oruka Therapeutics Inc.
5 BE0974487192 Oxurion N.V.

Anleihen/ETF

1 EU000A1Z99U9 Europäischer Stabilitätsmechanismus [ESM]
2 ES0L02505094 Spanien, Königreich
3 IT0005611139 CDP RETI S.p.A.
4 IT0005611063 Mediobanca - Banca di Credito Finanziario S.p.A.
5 XS2895057094 BMW International Investment B.V.
6 IT0005611055 Italien, Republik
7 LU2868143954 BNP Paribas Easy JPM ESG EMBI Global Diversified Composite UCITS ETF H CHF
8 LU2868144093 BNP Paribas Easy JPM ESG EMBI Global Diversified Composite UCITS ETF H GBP

Treibt Nvidias KI-Boom den Uranpreis?

In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.

Hier klicken

Zeit	Aktuelle Nachrichten
22.11.	ICANDY INTERACTIVE LIMITED: Response to ASX Price and Volume Query
03.11.	ICANDY INTERACTIVE LIMITED: ICI initiates legal action on former lemon sky executives
28.10.	ICANDY INTERACTIVE LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report
25.09.	ICANDY INTERACTIVE LIMITED: Notification of cessation of securities - ICI
03.09.	XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 03.09.2024	The following instruments on XETRA do have their first trading 03.09.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.09.2024 Aktien 1 AU000000ICI5 iCandy Interactive Ltd. 2... ► Artikel lesen

Zeit

Aktuelle Nachrichten

22.11.

ICANDY INTERACTIVE LIMITED: Response to ASX Price and Volume Query

03.11.

ICANDY INTERACTIVE LIMITED: ICI initiates legal action on former lemon sky executives

28.10.

ICANDY INTERACTIVE LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report

25.09.

ICANDY INTERACTIVE LIMITED: Notification of cessation of securities - ICI

03.09.

XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 03.09.2024

The following instruments on XETRA do have their first trading 03.09.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.09.2024 Aktien 1 AU000000ICI5 iCandy Interactive Ltd. 2...
► Artikel lesen

Zeit	Aktuelle Nachrichten
27.11.	Matinas BioPharma Holdings, Inc. - 8-K, Current Report
13.11.	Matinas BioPharma Holdings, Inc. - 10-Q, Quarterly Report
06.11.	MTNB stock touches 52-week low at $0.5 amid sharp annual decline
06.11.	MTNB-Aktie erreicht 52-Wochen-Tief bei 0,5 US-Dollar
31.10.	Matinas BioPharma mulls wind-down as antifungal therapy deal falls through

Zeit

Aktuelle Nachrichten

27.11.

Matinas BioPharma Holdings, Inc. - 8-K, Current Report

13.11.

Matinas BioPharma Holdings, Inc. - 10-Q, Quarterly Report

06.11.

MTNB stock touches 52-week low at $0.5 amid sharp annual decline

06.11.

MTNB-Aktie erreicht 52-Wochen-Tief bei 0,5 US-Dollar

31.10.

Matinas BioPharma mulls wind-down as antifungal therapy deal falls through

Zeit	Aktuelle Nachrichten
Do	Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody	Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy... ► Artikel lesen
Do	Oruka Therapeutics, Inc. - 8-K, Current Report
Mi	Oruka Therapeutics, Inc.: Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)	MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment... ► Artikel lesen
10.12.	Frazier Life Sciences Management L.P. Purchases New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)
14.11.	Oruka Therapeutics, Inc. - 8-K, Current Report

Zeit

Aktuelle Nachrichten

Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy...
► Artikel lesen

Oruka Therapeutics, Inc. - 8-K, Current Report

Oruka Therapeutics, Inc.: Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment...
► Artikel lesen

10.12.

Frazier Life Sciences Management L.P. Purchases New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

14.11.

Oruka Therapeutics, Inc. - 8-K, Current Report

Zeit	Aktuelle Nachrichten
Do	OXURION: French Authorities Approve Oxurion's Strategic Transaction Under Specific Conditions	LEUVEN, BELGIUM - 19 December 2024 - 6:00PM, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces that the French Ministry of the Economy, Finance... ► Artikel lesen
12.12.	OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC	Leuven, BELGIUM - December 12, 2024 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency... ► Artikel lesen
09.12.	OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC	Leuven, BELGIUM - December 9, 2024 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency... ► Artikel lesen
05.12.	OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas	Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital... ► Artikel lesen
02.12.	OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC	Leuven, BELGIUM - December 2, 2024 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency... ► Artikel lesen

Zeit

Aktuelle Nachrichten

OXURION: French Authorities Approve Oxurion's Strategic Transaction Under Specific Conditions

LEUVEN, BELGIUM - 19 December 2024 - 6:00PM, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces that the French Ministry of the Economy, Finance...
► Artikel lesen

12.12.

OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM - December 12, 2024 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen

09.12.

OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Leuven, BELGIUM - December 9, 2024 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen

05.12.

OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital...
► Artikel lesen

02.12.

OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM - December 2, 2024 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Fr	Rektron Group Inc. Announces Corporate Update and Access to Annual General Meeting Materials	NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / December 20, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)... ► Artikel lesen
10.12.	Rektron Group Inc. Announces Organizational Changes and Corporate Updates	NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / December 10, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)... ► Artikel lesen
30.11.	Rektron Group Inc. Announces Appointment of a New Director and Chairman	NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / November 30, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)... ► Artikel lesen
28.11.	Rektron Group Inc.: Rektron Reports Gross Profit of USD$30 Million for 2024, USD$2.5 Billion Revenue for Financial Year End July 31 2024	NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / November 27, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)... ► Artikel lesen
20.11.	Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates	NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATESVANCOUVER, BC / ACCESSWIRE / November 20, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Rektron Group Inc. Announces Corporate Update and Access to Annual General Meeting Materials

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / December 20, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)...
► Artikel lesen

10.12.

Rektron Group Inc. Announces Organizational Changes and Corporate Updates

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / December 10, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)...
► Artikel lesen

30.11.

Rektron Group Inc. Announces Appointment of a New Director and Chairman

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / November 30, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)...
► Artikel lesen

28.11.

Rektron Group Inc.: Rektron Reports Gross Profit of USD$30 Million for 2024, USD$2.5 Billion Revenue for Financial Year End July 31 2024

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / November 27, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)...
► Artikel lesen

20.11.

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN OR INTO THE UNITED STATESVANCOUVER, BC / ACCESSWIRE / November 20, 2024 / Rektron Group Inc. ("Rektron" or the "Company") (CSE:REK.U)(FRA:F75)...
► Artikel lesen

Unternehmen / Aktien	Kurs	%
ICANDY INTERACTIVE LIMITED	0,010	0,00 %
MATINAS BIOPHARMA HOLDINGS INC	0,054	0,00 %
ORUKA THERAPEUTICS INC	19,500	0,00 %
OXURION NV	0,249	+3,75 %
REKTRON GROUP INC	1,310	+3,97 %

Unternehmen / Aktien

Kurs

ICANDY INTERACTIVE LIMITED

0,010

0,00 %

MATINAS BIOPHARMA HOLDINGS INC

0,054

0,00 %

ORUKA THERAPEUTICS INC

19,500

0,00 %

OXURION NV